Sierra Oncology (NASDAQ: SRRA) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Sierra Oncology to related businesses based on the strength of its valuation, dividends, risk, analyst recommendations, institutional ownership, earnings and profitability.
Earnings & Valuation
This table compares Sierra Oncology and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sierra Oncology||N/A||-$47.86 million||-3.56|
|Sierra Oncology Competitors||$290.27 million||$35.99 million||51.64|
This table compares Sierra Oncology and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sierra Oncology Competitors||-5,322.24%||-84.37%||-35.66%|
This is a summary of recent ratings and target prices for Sierra Oncology and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sierra Oncology Competitors||949||3398||11903||239||2.69|
Sierra Oncology currently has a consensus price target of $4.00, suggesting a potential upside of 18.34%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.80%. Given Sierra Oncology’s rivals higher possible upside, analysts plainly believe Sierra Oncology has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
55.6% of Sierra Oncology shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.7% of Sierra Oncology shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
About Sierra Oncology
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.